21:05 , Apr 26, 2019 |  BioCentury  |  Product Development

Cytokinetics’ muscle gambit nears POC for next-gen therapies

Cytokinetics is banking that its nearly 15 years of muscle biology research will pay dividends with its next-generation therapies for cardiovascular and neuromuscular disorders. The next signal will come in early May when the biotech...
00:07 , Dec 22, 2017 |  BC Innovations  |  Strategy

Ovid spreads its wings

With its first two candidates for rare neurological disorders heading towards clinical proof of concept, Ovid Therapeutics Inc. is looking to capitalize on the experience it has gained to find compounds with differentiated pharmacology that...
20:19 , Dec 15, 2016 |  BC Innovations  |  Translation in Brief

Fore score

Cerecor Inc. (NASDAQ:CERC) has picked up a forebrain-selective anti-epileptic compound from Eli Lilly and Co. (NYSE:LLY) that could treat seizures by blocking AMPA glutamate receptor (GRIA; GLUR) without the dose-limiting motor side effects associated with...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Insomnia Orexin 1 receptor (HCRTR1; OX1R); HCRTR2 (OX2R) Rat and nonhuman primate studies suggest antagonizing orexin receptors could help treat insomnia...
07:00 , Sep 10, 2012 |  BioCentury  |  Emerging Company Profile

Putting a Lid on PDE-4

Efforts to directly inhibit phosphodiesterase-4 's active site to treat neurological indications have failed due to dose-limiting toxicities. Tetra Discovery Partners LLC is trying to take side effects out of the equation with allosteric inhibitors...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

EHT 0202: Phase IIa data

Top-line data from 159 patients with mild to moderate AD in a double-blind, placebo-controlled, French Phase IIa trial showed that 40 or 80 mg oral EHT 0202 twice daily in combination with an acetylcholinesterase inhibitor...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Clinical News

EHT 0202: Completed Phase IIa enrollment

ExonHit completed enrollment of about 150 patients with mild to moderate AD in a double-blind, placebo-controlled, French Phase IIa trial evaluating 40 or 80 mg oral EHT 0202 given twice daily in combination with an...
07:00 , May 22, 2008 |  BC Innovations  |  Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Photoaffinity labeling of g-aminobutyric acid (GABA) receptors in living cells A three-part fluorescent probe may be useful for investigating GABAB receptor function in...
07:00 , Mar 31, 2008 |  BC Week In Review  |  Clinical News

EHT 0202: Phase I data

Data from a double-blind, placebo-controlled, single-dose, 4-arm, crossover Phase I trial in 12 volunteers showed that 40 mg EHT 0202 significantly improved scopolamine-induced reductions in vigilance level 75 minutes post-dose, as assessed using spectral analysis...